Protocol Ledger

NCT05541822 · Phase II · RECRUITING

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Interventional Phase II clinical trial protocol NCT05541822 sponsored by Abion in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-01-17 Enrollment: 178 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05541822
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)178 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05541822
Protocol FieldVerified Registry Value
NCT IdentifierNCT05541822
Consolidated Lead SponsorAbion
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment178 participants (ESTIMATED)
Registered Start Date2023-01-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05541822
Hospital Research SiteLocationSite Profile
MD Anderson Cancer CenterHouston, TXOpen Hospital Dossier ->
National Cancer CenterGoyang-si, South KoreaOpen Hospital Dossier ->
Ajou University HospitalSuwon, South KoreaOpen Hospital Dossier ->
Korea University Anam HospitalSeoul, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI